Clinuvel Pharmaceuticals (ADR) (CUVL)
Commercializes SCENESSE® for adult EPP and develops melanocortin therapies.
$5.84
vs last close+0.04 (+0.65%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Feb '23Aug '23Feb '24Aug '24Feb '25Aug '25Feb '26Aug '26
Reported$0.15$0.24$0.14$0.34$0.18$0.29$0.15$0.34
Estimate$0.17$0.25$0.17$0.30$0.14$0.18$0.20$0.35
Surprise−13.3%−3.4%−18.9%+13.5%+28.5%+57.6%−25.9%−3.5%
RevenueReportedEstimate
Feb '23Aug '23Feb '24Aug '24Feb '25Aug '25Feb '26Aug '26
Reported$19.7M$31.6M$21.1M$38.0M$22.3M$38.8M$26.2M$41.1M
Estimate$22.5M$34.1M$23.1M$36.6M$21.6M$40.0M$25.7M$42.2M
Surprise−12.2%−7.5%−8.4%+3.8%+3.2%−3.2%+2.2%−2.8%
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Feb 2027 | $0.18 | — | — |
| Aug 2026 | $0.35 | $0.34 | −3.5% |
| Feb 2026 | $0.20 | $0.15 | −25.9% |
| Aug 2025 | $0.18 | $0.29 | +57.6% |
| Feb 2025 | $0.14 | $0.18 | +28.5% |
| Aug 2024 | |||
| Feb 2024 | |||
| Aug 2023 | |||
| Feb 2023 | |||
| Aug 2022 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Feb 23, 2027 | $0.18 | — | — | $26.0M | — | — | — |
| Aug 26, 2026 | $0.35 | $0.34 | −3.5% | $42.2M | $41.1M | −2.8% | −11.4% |
| Feb 25, 2026 | $0.20 | $0.15 | −25.9% | $25.7M | $26.2M | +2.2% | — |
| Aug 27, 2025 | $0.18 | $0.29 | +57.6% | $40.0M | $38.8M | −3.2% | — |
| Feb 26, 2025 | $0.14 | $0.18 | +28.5% | $21.6M | $22.3M | +3.2% | — |
| Aug 28, 2024 | |||||||
| Feb 21, 2024 | |||||||
| Aug 29, 2023 | |||||||
| Feb 23, 2023 | |||||||
| Aug 29, 2022 |